此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi

2021年6月3日 更新者:University of North Carolina, Chapel Hill

Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi: A Randomized Controlled Trial in Lilongwe

There is promising evidence that couple-based approaches within Malawi's Option B+ prevention of mother to child transmission program could address help address 1) poor male engagement in the HIV continuum of care, 2) low male adoption of biomedical HIV prevention approaches, 3) sub-optimal female engagement in the continuum of care, and 4) poor or uncertain infant outcomes. Our team has developed an intervention to address these challenges, and will conduct a randomized controlled trial (N=500 couples) to assess intervention effectiveness at one year. Women with recent HIV infections enrolled in this trial will be compared against a cohort of 350 HIV-uninfected women to explore predictors of HIV acquisition in pregnancy in Malawi.

研究概览

详细说明

In sub-Saharan Africa, engaging HIV-infected men in HIV care and treatment and engaging HIV-uninfected men in prevention has proven challenging. Along all steps of the HIV care-seeking cascade, men exhibit worse care-seeking behaviors. They are less likely to seek HIV testing and counseling (HTC), initiate combination antiretroviral therapy (cART), and be retained in cART care. Poor care-seeking has resulted in a lower prevalence of viral suppression and earlier mortality. Additionally, men rarely engage in the antenatal care-seeking of their female sexual partners, leading to worse maternal and infant outcomes. This low level of engagement has been noted in Malawi's Option B+ prevention of mother to child transmission (PMTCT) program, and has been a critical barrier to female Option B+ uptake and retention, and a missed opportunity for engaging men.

There is promising evidence that couple-based approaches within Malawi's Option B+ prevention of mother to child transmission program could address all of these challenges: poor male engagement in the HIV continuum of care, low male adoption of biomedical HIV prevention approaches, sub-optimal female engagement in the continuum of care, and poor or uncertain infant outcomes. Our team has designed a couples-based intervention to address these challenges, and will conduct a randomized controlled trial (N=500 couples) to assess intervention effectiveness at one year. Results from this study are expected to inform how best to address family outcomes in an Option B+ program.

This study has the following aims described below:

Aim 1: Determine whether the couple-based intervention increases new HIV-positive diagnoses among HIV-infected male sex partners, helps HIV-infected men engage and remain in care, and contributes to male viral suppression compared to individual standard of care. The investigators will compare the couple-based intervention to standard of care for increasing the proportion of men who are aware of being HIV-infected, the proportion of these men who initiate and remain in cART care, and the proportion of these men with viral suppression at one year.

Aim 2: Determine whether the couple-based intervention identifies HIV-discordant couples and decreases the likelihood of male exposure to HIV compared to individual standard of care. The investigators will compare the intervention to standard of care for increasing the number of men with non-HIV exposure from their female partner through consistent condom use, viral suppression, abstinence, or a combination of these methods over one year.

Aim 3: Determine whether the couple-based intervention improves female cART retention and viral suppression compared to individual standard of care. The investigators will compare the intervention to standard of care for female cART retention and viral suppression at one year.

Aim 4: Determine whether the couple-based intervention improves infant early infant diagnosis uptake compared to individual standard of care. Explore uptake of early infant diagnosis and rates of mother-to-child transmission and child survival in the two intervention arms.

Aim 5: Develop an in-depth understanding of HIV transmission dynamics in Lilongwe. Using the biomarkers and behavioral survey, we will seek to understand transmission timing, direction, and context in Lilongwe. We will compare women with recent HIV infection to a population of HIV-uninfected controls (n=350) to understand predictors of HIV acquisition in pregnancy in Malawi.

研究类型

介入性

注册 (实际的)

1116

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Central District
      • Lilongwe、Central District、马拉维
        • Bwaila District Hospital Antenatal Unit

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

15年 及以上 (孩子、成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria (HIV-infected Women):

  • HIV-infected and eligible for Option B+
  • >18 years old or 15-17 years old and married
  • Planning to remain in the Bwaila catchment area for the next year or notify the study team if they leave the area or change facilities
  • Part of a heterosexual relationship for >3 months

    • Expects the partner to be in the relevant catchment area for at least one week in the next six months.
    • Able and willing to give locator information for this partner
    • Willing to have study staff conduct phone and physical tracing of that partner
    • Willing to undergo a couple-based intervention with this partner
  • Able and willing to provide informed consent

Inclusion Criteria (Male Partners of HIV-infected women)

  • >18 years old or 15-17 years old and married
  • In a relationship with the female partner for >3 months

    • Willing to undergo a couples-based intervention with their female partner
  • Able and willing to provide informed consent

Inclusion Criteria (HIV-uninfected Women):

  • HIV-uninfected
  • >18 years old or 15-17 years old and married
  • Part of a heterosexual relationship for >3 months

    • Expects the partner to be in the relevant catchment area for at least one week in the next six months.
    • Willing to receive couples-based HIV testing and counseling with this partner
  • Able and willing to provide informed consent

Exclusion Criteria (all Women and Male Partners):

• Any condition that in the opinion of the study investigator would compromise the ability of the prospective participant to provide informed consent, undergo study procedures safely, or would prevent proper conduct of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Individual (SOC)
HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
实验性的:Couple (Intervention)
In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.

Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.

Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another.

其他名称:
  • male engagement intervention
无干预:HIV-Uninfected Cohort
HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Women Retained in Care
大体时间:12 months
Women who presented at 12 months and reported taking at least one dose of ART in the last seven days
12 months
Number of Women With Viral Suppression
大体时间:12 months
Women who presented at 12 months with a viral load <1000 copies/mL
12 months
Number of HIV-positive Male Partners Aware of Their HIV-positive Status
大体时间:12 months
HIV-positive male partners who presented at 12 months and reported knowing they were HIV-positive prior to receiving the results of the HIV test conducted at the 12 month study visit
12 months
Number of HIV-positive Male Partners Retained in Care
大体时间:12 months
HIV-positive male partners who presented at 12 months and reported taking at least one dose of ART in the last seven days
12 months
Number of HIV-positive Male Partners With Viral Suppression
大体时间:12 months
HIV-positive male partners who presented at 12 months with a viral load <1000 copies/mL
12 months
Number of HIV-negative Men Without HIV Exposure From Their Primary Partner
大体时间:12 months
HIV-negative men with a) consistent condom use in the last six months or b) a suppressed female partner or c) abstinence with primary partner
12 months

次要结果测量

结果测量
措施说明
大体时间
Number of HIV-positive Female Participants Who Reported Early Infant Diagnosis
大体时间:12 months
HIV-positive female participants who reported a live birth and uptake of early infant diagnosis
12 months
Predictors of Recent HIV Infection
大体时间:At the day of female consent
Risk factor analysis to identify predictors of recent HIV infection among pregnant women
At the day of female consent

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nora E Rosenberg, PhD、University of North Carolina, Chapel Hill

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年9月25日

初级完成 (实际的)

2020年7月21日

研究完成 (实际的)

2020年9月30日

研究注册日期

首次提交

2018年3月19日

首先提交符合 QC 标准的

2018年3月19日

首次发布 (实际的)

2018年3月26日

研究记录更新

最后更新发布 (实际的)

2021年6月24日

上次提交的符合 QC 标准的更新

2021年6月3日

最后验证

2021年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • 17-0681
  • R00MH104154 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅